Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 10 October 2026
2018-11-23 09:39:00 Friday ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm electio
2020-03-12 09:32:00 Thursday ET

Google CEO Eric Schmidt and his co-authors show the innovative corporate culture and mission of the Internet search tech titan. Eric Schmidt, Jonathan Ro
2020-11-24 09:30:00 Tuesday ET

Many analytic business competitors can apply smart data science to support their distinctive capabilities and strategic advantages. Thomas Davenport and
2018-02-27 09:35:00 Tuesday ET

Fed's new chairman Jerome Powell testifies before Congress for the first time. He vows to prevent price instability for U.S. consumers, firms, and finan
2018-05-15 08:40:00 Tuesday ET

Net neutrality rules continue to revolve around the Trump administration's current IT agenda of 5G telecom transformation. Republican Senate passes the
2018-05-01 11:38:00 Tuesday ET

America and China play the game of chicken over trade and technology, whereas, most market observers and economic media commentators hope the Trump team to